{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T22:33:09Z","timestamp":1649197989288},"reference-count":57,"publisher":"Consilium Medicum","issue":"5","license":[{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim: to evaluate the role of laboratory biomarkers in monitoring effectiveness of rituximab (RTM) biosimilar therapy in a total dose of 1200 mg. Materials and methods. 20 patients (pts) with rheumatoid arthritis (RA) (18 woman, mean age 61.5(54-66.5) years, mean disease duration 39.5(20-84) months, mean DAS28 5.6(4.9-6.8)) received two intravenous RTM biosimilar infusions (600 mg \u21162) in combination with DMARDs and glucocorticoids. Laboratory biomarkers were assessed at baseline and weeks 12 and 24 after the first infusion of RTX. Results. RTM biosimilar induced decreases in DAS28, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) at week 12 and 24, p<\/jats:p>","DOI":"10.26442\/00403660.2019.05.000230","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T11:37:45Z","timestamp":1561549065000},"page":"26-33","source":"Crossref","is-referenced-by-count":0,"title":["The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, \u201cBIOCAD\u201d) in patients with rheumatoid arthritis"],"prefix":"10.26442","volume":"91","author":[{"given":"A S","family":"Avdeeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M V","family":"Cherkasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Kusevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V V","family":"Rybakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A S","family":"Artyuhov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eh B","family":"Dashinimaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N V","family":"Chichasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E L","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"ref1","unstructured":"\u041d\u0430\u0441\u043e\u043d\u043e\u0432 \u0415.\u041b., \u041a\u0430\u0440\u0430\u0442\u0435\u0435\u0432 \u0414.\u0415., \u0411\u0430\u043b\u0430\u0431\u0430\u043d\u043e\u0432\u0430 \u0420.\u041c. \u0420\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u043d\u044b\u0439 \u0430\u0440\u0442\u0440\u0438\u0442. \u0412 \u043a\u043d.: \u0420\u0435\u0432\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. \u041d\u0430\u0446\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u043e\u0435 \u0440\u0443\u043a\u043e\u0432\u043e\u0434\u0441\u0442\u0432\u043e. \u041f\u043e\u0434 \u0440\u0435\u0434. \u0415.\u041b. \u041d\u0430\u0441\u043e\u043d\u043e\u0432\u0430, \u0412.\u0410. \u041d\u0430\u0441\u043e\u043d\u043e\u0432\u043e\u0439. \u041c.: \u0413\u042d\u041e\u0422\u0410\u0420-\u041c\u0435\u0434\u0438\u0430, 2008: 290-331."},{"key":"ref2","unstructured":"\u041d\u0430\u0441\u043e\u043d\u043e\u0432 \u0415.\u041b. \u0420\u0438\u0442\u0443\u043a\u0441\u0438\u043c\u0430\u0431. \u0412 \u043a\u043d.: \u0413\u0435\u043d\u043d\u043e - \u0438\u043d\u0436\u0435\u043d\u0435\u0440\u043d\u044b\u0435 \u0431\u0438\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u044b \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u043d\u043e\u0433\u043e \u0430\u0440\u0442\u0440\u0438\u0442\u0430. \u041f\u043e\u0434 \u0440\u0435\u0434. \u0415.\u041b. \u041d\u0430\u0441\u043e\u043d\u043e\u0432\u0430. \u041c.: \u0418\u041c\u0410-\u041f\u0420\u0415\u0421\u0421, 2013:200-221."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Huscher D, Mittendorf T, von Hinuber U, et al. Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis. 2015;74(4):738-45. doi.org\/10.1136\/annrheumdis-2013-204311","DOI":"10.1136\/annrheumdis-2013-204311"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14412\/1995-4484-2016-628-640"},{"key":"ref5","unstructured":"\u0424\u0435\u0434\u0435\u0440\u0430\u043b\u044c\u043d\u044b\u0439 \u0437\u0430\u043a\u043e\u043d \u043e\u0442 22 \u0434\u0435\u043a\u0430\u0431\u0440\u044f 2014 \u0433. \u2116429-\u0424\u0417 \u00ab\u041e \u0432\u043d\u0435\u0441\u0435\u043d\u0438\u0438 \u0438\u0437\u043c\u0435\u043d\u0435\u043d\u0438\u0439 \u0432 \u0424\u0435\u0434\u0435\u0440\u0430\u043b\u044c\u043d\u044b\u0439 \u0437\u0430\u043a\u043e\u043d \"\u041e\u0431 \u043e\u0431\u0440\u0430\u0449\u0435\u043d\u0438\u0438 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0445 \u0441\u0440\u0435\u0434\u0441\u0442\u0432\"\u00bb. \u041f\u0440\u0438\u043d\u044f\u0442 \u0413\u043e\u0441\u0443\u0434\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u0414\u0443\u043c\u043e\u0439 9 \u0434\u0435\u043a\u0430\u0431\u0440\u044f 2014 \u0433. \u041e\u0434\u043e\u0431\u0440\u0435\u043d \u0421\u043e\u0432\u0435\u0442\u043e\u043c \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 17 \u0434\u0435\u043a\u0430\u0431\u0440\u044f 2014 \u0433."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0232-7"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0233-6"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209540"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"\u041d\u0430\u0441\u043e\u043d\u043e\u0432 \u0415.\u041b., \u0417\u043e\u043d\u043e\u0432\u0430 \u0415.\u0412., \u0418\u0432\u0430\u043d\u043e\u0432\u0430 \u041e.\u041d., \u041a\u043d\u044f\u0437\u0435\u0432\u0430 \u041b.\u0410., \u041c\u0430\u0437\u0443\u0440\u043e\u0432 \u0412.\u0418. \u0438 \u0434\u0440. \u0420\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u0441\u0440\u0430\u0432\u043d\u0438\u0442\u0435\u043b\u044c\u043d\u043e\u0433\u043e \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f III \u0444\u0430\u0437\u044b \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u043e\u0432 \u0440\u0438\u0442\u0443\u043a\u0441\u0438\u043c\u0430\u0431 (\u0410\u0446\u0435\u043b\u043b\u0431\u0438\u044f \u0438 \u041c\u0430\u0431\u0442\u0435\u0440\u0430) \u043f\u0440\u0438 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u043d\u043e\u043c \u0430\u0440\u0442\u0440\u0438\u0442\u0435 (\u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0435 BIORA). \u041d\u0430\u0443\u0447\u043d\u043e - \u043f\u0440\u0430\u043a\u0442\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2016;54(5):510-9. https:\/\/doi.org\/10.14412\/1995-4484-2016-510-519","DOI":"10.14412\/1995-4484-2016-510-519"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bredemeier M, de Oliveira F.K, Rocha C.M. Low - versus High - dose rituximab for rheumatoid arthritis: a systemic review and metaanalysis. Arthritis Care Res. 2014;66:228-35. https:\/\/doi.org\/10.1002\/acr.22116","DOI":"10.1002\/acr.22116"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144998"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008933"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"\u041d\u0430\u0441\u043e\u043d\u043e\u0432 \u0415.\u041b., \u041c\u0430\u0437\u0443\u0440\u043e\u0432 \u0412.\u0418., \u0417\u043e\u043d\u043e\u0432\u0430 \u0415.\u0412., \u041a\u043d\u044f\u0437\u0435\u0432\u0430 \u041b.\u0410., \u041c\u0430\u0440\u0443\u0441\u0435\u043d\u043a\u043e \u0418.\u041c. \u0438 \u0434\u0440. \u042d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0438 \u0431\u0435\u0437\u043e\u043f\u0430\u0441\u043d\u043e\u0441\u0442\u044c \u0431\u0438\u043e\u0430\u043d\u0430\u043b\u043e\u0433\u0430 \u0440\u0438\u0442\u0443\u043a\u0441\u0438\u043c\u0430\u0431\u0430 (\u0410\u0446\u0435\u043b\u043b\u0431\u0438\u044f\u00ae) \u043f\u0440\u0438 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u043d\u043e\u043c \u0430\u0440\u0442\u0440\u0438\u0442\u0435 \u0432 \u043a\u0430\u0447\u0435\u0441\u0442\u0432\u0435 \u00ab\u043f\u0435\u0440\u0432\u043e\u0433\u043e\u00bb \u0433\u0435\u043d\u043d\u043e - \u0438\u043d\u0436\u0435\u043d\u0435\u0440\u043d\u043e\u0433\u043e \u0431\u0438\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430: \u0440\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f III \u0444\u0430\u0437\u044b (ALTERRA). \u041d\u0430\u0443\u0447\u043d\u043e - \u043f\u0440\u0430\u043a\u0442\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2017;55(4):351-9. https:\/\/doi.org\/10.14412\/1995-4484-2017-351-359","DOI":"10.14412\/1995-4484-2017-351-359"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.01.007"},{"key":"ref15","unstructured":"Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti - cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long - standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196."},{"key":"ref16","unstructured":"\u0410\u043b\u0435\u043a\u0441\u0430\u043d\u0434\u0440\u043e\u0432\u0430 \u0415.\u041d., \u0410\u0432\u0434\u0435\u0435\u0432\u0430 \u0410.\u0421., \u041b\u0443\u043a\u0438\u043d\u0430 \u0413.\u0412., \u041d\u043e\u0432\u0438\u043a\u043e\u0432 \u0410.\u0410., \u0427\u0435\u0440\u043a\u0430\u0441\u043e\u0432\u0430 \u041c.\u0412., \u041f\u043e\u043f\u043a\u043e\u0432\u0430 \u0422.\u0412., \u041b\u0438\u043d\u0435\u0432\u0430 \u041e.\u0413., \u041a\u0443\u0437\u0438\u043a\u044f\u043d\u0446 \u041a.\u0425., \u041d\u0430\u0441\u043e\u043d\u043e\u0432 \u0415.\u041b. \u041a\u043b\u0438\u043d\u0438\u043a\u043e - \u0438\u043c\u043c\u0443\u043d\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u044d\u0444\u0444\u0435\u043a\u0442\u044b \u0430\u043d\u0442\u0438-\u0412-\u043a\u043b\u0435\u0442\u043e\u0447\u043d\u043e\u0439 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u0443 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u043d\u044b\u043c \u0430\u0440\u0442\u0440\u0438\u0442\u043e\u043c. \u041d\u0430\u0443\u0447\u043d\u043e - \u043f\u0440\u0430\u043a\u0442\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2012;50(1):14-21. https:\/\/doi.org\/ 10.14412\/1995-4484-2012-498"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.21650"},{"key":"ref18","unstructured":"Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti - tumor necrosis factor therapy. Results of multicenter, randomized, double - blind, placebo - controlled, phase III trial evaluating primary efficacy and safety at twenty - four weeks. Arthritis Rheum. 2006;54:2793-806. https:\/\/doi.org\/10.1002\/art. 22025"},{"key":"ref19","unstructured":"Higashida J, Wun T, Schmidt S. Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis Refractory to Disease Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor - a Treatment. Rheumatology. 2005;32:2109-15."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets & Therapy. 2008;2:911-6. https:\/\/doi. org\/10.2147\/BTT.S3939","DOI":"10.2147\/BTT.S3939"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Bokarewa M, Lindholm C, Zendjanchi K, et al. Efficacy of Anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate\/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. https:\/\/doi.org\/10.1111\/j.1365-3083.2007.01995.x","DOI":"10.1111\/j.1365-3083.2007.01995.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66: 818-20. https:\/\/doi.org\/10.1136\/ard.2006.062505","DOI":"10.1136\/ard.2006.062505"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Vizioli C, Viana V, Ribeiro A. Auto - antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71(Suppl 3):667.","DOI":"10.1136\/annrheumdis-2012-eular.519"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005580"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000009"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60975"},{"key":"ref27","unstructured":"Harre U, Lang S.C, Pfeifle R, et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone lose. Nat Communocation. 2015. doi: 10.1038\/ ncomms7651"},{"key":"ref28","unstructured":"\u041d\u0430\u0441\u043e\u043d\u043e\u0432 \u0415.\u041b. \u041f\u0440\u043e\u0431\u043b\u0435\u043c\u044b \u0438\u043c\u043c\u0443\u043d\u043e\u043f\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u043d\u043e\u0433\u043e \u0430\u0440\u0442\u0440\u0438\u0442\u0430: \u044d\u0432\u043e\u043b\u044e\u0446\u0438\u044f \u0431\u043e\u043b\u0435\u0437\u043d\u0438. \u041d\u0430\u0443\u0447\u043d\u043e - \u043f\u0440\u0430\u043a\u0442\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2017;55(3):277-94"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Bugatt S, Bogliolo L,Vitolo B, et al. Anti - citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther. 2016;18:226. doi: 10.1186\/s 13075- 016-1116-9","DOI":"10.1186\/s13075-016-1116-9"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis2015-208"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.07.002"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209124.68"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Engel P, G\u00f3mez-Puerta J, Ramos-Casals M, et al. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev. 2011;63:127-56. doi.org\/10.1124\/pr.109.002006","DOI":"10.1124\/pr.109.002006"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Lund F. Cytokine - producing B lymphocytes - key regulators of immunity. Curr Opin Immunol. 2008;20:332-8. doi.org\/10.1016\/j.coi.2008.03.003","DOI":"10.1016\/j.coi.2008.03.003"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Manjarrez-Ordu\u00f1o N, Qu\u00e1ch T, Sanz I, et al. B cells and immunological tolerance. J Invest Dermatol. 2009;129:278-88.","DOI":"10.1038\/jid.2008.240"},{"key":"ref36","unstructured":"Blom M, Wenink M.H, Huijbens R.J.F, et al. Altered circulating cytokine pattern after administration of rituximab is correlated with response to therapy in rheumatoid arthritis. Arthritis Rheum. 2008;26(Suppl):764."},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Fabre S, Gvisset C, Tatem L, et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol. 2008;155:395-402. doi.org\/10.1111\/j.1365-2249.2008.03804.x","DOI":"10.1111\/j.1365-2249.2008.03804.x"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Szekanecz Z, Koch A. Successes and failures of chemokine - pathway targeting in rheumatoid arthritis. Nat Rev Rheumatol. 2016 Jan;12(1):5-13. doi: 10.1038\/ nrrheum.2015.157. https:\/\/doi.org\/10.1038\/nrrheum.2015.157","DOI":"10.1038\/nrrheum.2015.157"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Elyaman W, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci. 2009;106:12885-90. doi.org\/10.1073\/pnas.0812530106","DOI":"10.1016\/j.clim.2009.03.093"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Nowak E.C, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med. 2009;206:1653-60. doi.org\/10.1084\/jem.20090246","DOI":"10.1084\/jem.20090246"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Bober L.A, et al. Regulatory effects of interleukin-4 and interleukin-10 on human neutrophil function ex vivo and on neutrophil influx in a rat model of arthritis. Arthritis Rheum. 2000;43:2660-7. doi.org\/10.1002\/1529-0131(200012)43:12<26 60::aid-anr5>3.0.co;2-4","DOI":"10.1002\/1529-0131(200012)43:12<2660::AID-ANR5>3.0.CO;2-4"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Smallie T, et al. IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. J Exp Med. 2010;207:2081-8. doi.org\/10.1084\/jem.20100414","DOI":"10.1084\/jem.20100414"},{"key":"ref43","unstructured":"Van Roon J, et al. Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol. 2003;30:648-51."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Wong C.K, et al. Effects of inflammatory cytokine IL-27 on the activation of fibroblast - like synoviocytes in rheumatoid arthritis. Arthritis Res Ther. 2010;12:R129. doi.org\/10.1186\/ar3067","DOI":"10.1186\/ar3067"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Emery P, Fleishmann R, Filipowicz-Sosnowska A, et al. For the DANCER Study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double - blind, placebo - controlled dose - range trial. Arthritis Rheum. 2006;54:1390-400. doi.org\/10.1002\/art.21778","DOI":"10.1002\/art.21778"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Emery P, Deodhar A, Rigby W, et al. Efficacy and Safety of different doses and retreatment of Rituximab: a randomized, placebo - controlled trial in patients who are biologically na\u00efve with active rheumatoid arthritis and anadequate response to methotrexate (Study Evaluating Rituximab`s Efficacy in MTX inadequate responders (SERENA). Ann Rheum Dis. 2010;69:1629-35. doi.org\/10.1136\/ard.20 09.119933","DOI":"10.1136\/ard.2009.119933"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Rubbert-Roth A, Tak P, Zebrini C, et al. Efficacy and safety of various repeat treatment dosing regimes in Rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR) dosing regimens of rituximab in patients with active RA: results of a phase III randomized study (MIRROR). Rheumatology. 2010;49:1683-93. doi.org\/10.1093\/rheumatology\/keq401","DOI":"10.1093\/rheumatology\/keq116"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Roll P, Dorner T, Tony H-P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58:1566-75. doi.org\/10.1002\/art.23473","DOI":"10.1002\/art.23473"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Van Vollenhoven R.F, Emery P, Bingham C.O, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37:558-67. doi.org\/10.3899\/jrheum.090856","DOI":"10.3899\/jrheum.090856"},{"key":"ref50","unstructured":"Mariette X, Kivitz A, Isaacs J, et al. Effectiveness of Rituximab (RTX) + methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) and disease charaxteristics associated with poor outcomes. Arthritis Rheum. 2009;60 (Suppl):631."},{"key":"ref51","unstructured":"Tak P, Cohen S, Emery P, et al. Baseline autoantibody status (RF, ant-CCP) and clinical response following the first treatment course with rituximab. Arthritis Rheum. 2006;54(Suppl 9):368."},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Tak P, Rigby W, Rubbert-Roth A. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. doi.org\/10.1136\/ard.2010.137703","DOI":"10.1136\/ard.2010.137703"},{"key":"ref53","unstructured":"Khan A, Mahmud T, Hammond T, et al. Rituximab (RTX) is more effective in active sero - positive RA than sero - negative RA. Arthritis Rheum. 2010;62(Suppl 10):1830."},{"key":"ref54","unstructured":"Isaacs J.D, Olech E, Tak P.P, et al. Autoantibody - positive rheumatoid arthritis patients have enchanced clinical response when compared with seronegative patients. Ann Rheum Dis. 2009;68(Suppl 3):442."},{"key":"ref55","unstructured":"Silverman G, Schwartzman S, Townsend M, et al. Identification of biomarkers for enhanced benefit to Rituximab in rheumatoid arthritis: role for autoantibodies and inflammatory markers. Arthritis Rheum. 2009;60(Suppl.):628."},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six - month, national, multicenter, open - label study. Arthritis Rheum. 2011;63:933-8. doi.org\/ 10.1002\/art.30233","DOI":"10.1002\/art.30233"},{"key":"ref57","unstructured":"Thurling R, Boumans M, Vos K, et al. Early changes in serum levels of cytokines and chemokines are predictive of the response to Rituximab treatment in rheumatoid arthritis. Arthritis Rheum. 2009;60(Suppl.):630."}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33578\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33578\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T21:51:33Z","timestamp":1634161893000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2019.05.000230","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,15]]}}}